Definitive Contract W81XWH15C0101
Award Date 8/17/15
Potential Completion Date 8/31/20
Potential Value $3.6M
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Buffalo, NY 14203, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a federal contract award by the Department of Health and Human Services (HHS) to Cleveland Biolabs, Inc., a small business, under the Small Business Innovation Research (SBIR) program. The contract is for the development of "RADIOPROTECTORS TARGETING P53" and has a potential value of $1,499,998.00. The contract is a cost-plus-fixed-fee definitive contract with a period of performance ending on August 31, 2008. The place of performance is Cleveland, Ohio. This contract award...
- This is a $1,299,969.27 Firm Fixed Price Definitive Contract awarded by the Defense Health Agency (DHA) to CFD Research Corporation, a small business, for a Small Business Technology Transfer (STTR) Phase II medical research project. The contract is for the development of a multiplexed multi-omics biomarker panel from minimally invasive biomatrix, with a final completion date of January 19, 2027. CFD Research Corporation has extensive experience in federal contract awards, including prime and...
- This federal contract award, valued at $228,367.47, was issued by the Defense Health Agency to Leidos, Inc. under a Delivery Order contract for the FY23 Bone Marrow Failure Research Program. The contract involves vision setting, pre-application screening, and programmatic review services, to be performed at Fort Detrick, MD. The contract is a Cost Plus Fixed Fee arrangement and does not have a set-aside designation. Leidos, Inc. is the prime contractor, and the parent company is Leidos Holdings,...
- This is a $4,102,685.00 definitive contract awarded to The Cleveland Clinic Foundation, a non-profit academic medical center, by the National Heart Lung and Blood Institute, a civilian agency within the U.S. Department of Health and Human Services. The contract is for biomedical research and services, with no set-aside designation. The Cleveland Clinic Foundation operates through its Finance/Academic Affairs Fiscal Services Division and does business as the Cleveland Clinic Health System. As a...
- This is a Cost Plus Fixed Fee contract awarded by the National Cancer Institute, a civilian agency, to Buffalo Biolabs, LLC, a small business, for the development of anticancer agents under the Small Business Innovation Research (SBIR) program. The award amount is $1,496,764.00 and the period of performance is until October 31, 2014. The contract is a Phase II SBIR action, which indicates it is for the continued development and testing of a promising technology that was previously funded under a...
- <p>This is a federal contract award from the National Cancer Institute (NCI), a civilian agency, to Buffalo Biolabs, LLC, a small business. The contract, awarded on September 20, 2012, is for "OTHER FUNCTIONS R & D - MEDICAL BIOMEDICAL (BASIC RESEARCH)" and has a ceiling value of $200,000.00. The contract type is Definitive Contract with a Firm Fixed Price pricing type. The period of performance ends on August 5, 2013. This contract award is set aside for total small business.</p>
- This is a Cost Plus Fixed Fee delivery order contract awarded by the Defense Health Agency to Leidos, Inc. for FY23 TICK-BORNE DISEASE RESEARCH PROGRAM SUPPORT SERVICES on behalf of the Congressionally Directed Medical Research Program. The contract has a ceiling value of $187,330.77 and a period of performance through June 9, 2024. The contract was not set aside for any specific business category. Leidos, Inc. is a global leader in information technology, engineering, and science solutions,...
- This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute, part of the National Institutes of Health at the Department of Health and Human Services, to Leidos Biomedical Research Inc. to provide a HIGH-PLEX PHARMACODYNAMIC BIOMARKER ASSAY. The potential value of the contract is $25,266,647.00 and it does not have a set-aside designation. Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc. and has served as both a prime contractor and...
- This contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH), specifically the National Cancer Institute, to the prime contractor Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The award has a potential value of $11,193,302.00 and is a delivery order contract with a cost-plus-fixed-fee pricing structure. The contract was awarded on September 25, 2019, with a completion date of August 30, 2024. This contract is not set aside...
- This is a federal contract award to Leidos, Inc. for the Bone Marrow Failure Research Program. The contract provides vision setting, pre-application screening, programmatic review, and general program support services for this research program. It is a cost-plus-fixed-fee contract with a ceiling value of $310,470.62 and a performance period ending on April 30, 2026. The contract was awarded by the Defense Health Agency, a component of the Department of Defense. Leidos, Inc. is a large,...